BUDAPEST, Hungary (AP) — Hungarian legislation banning the availability of LGBTQ+ content to minors violates European Union law and breaches a foundational treaty guaranteeing respect for human rights and equality, the bloc’s court ruled Tuesday.
The European Court of Justice said that Hungary's legislation, adopted in 2021 by the nationalist-populist government of outgoing Prime Minister Viktor Orbán, “stigmatizes and marginalizes" LGBTQ+ persons, and fails to uphold the EU's prohibition of discrimination based on sex or sexual orientation.
Hungary’s law, which was widely criticized by human rights groups, prohibited the display of content to minors that depicts homosexuality or gender change, while also providing harsher penalties for crimes of pedophilia.
The government argued its policies, including a more recent law and constitutional amendment that effectively banned the popular Budapest Pride event, sought to protect children from what it calls “sexual propaganda.”
But critics of the legislation have compared it to Russia’s gay propaganda law of 2013, and say it conflates homosexuality with pedophilia. Last year, over 100,000 people took part in a Budapest Pride march in defiance of the government's ban.
In its ruling, the Luxembourg-based court found that, for the first time in an action brought against one of the EU's 27 member states, Hungary had violated Article 2 of the bloc's foundational treaty, which defines “the values of respect for human dignity, freedom, democracy, equality, the rule of law and respect for human rights, including the rights of persons belonging to minorities.”
It also found that the law breached rules relating to services in the EU's internal market, as well as data protection laws.
Orbán's government was defeated in a landslide election on April 12 by the center-right Tisza party and its leader, Péter Magyar, bringing an end to Orbán's 16 years in power.
Magyar's government is expected to take office in mid-May, and has pledged to pursue a more constructive approach to its relationship with the EU.
During his election campaign, Magyar was cautious about engaging in Orbán's culture-war debate over LGBTQ+ rights. But in his April 12 victory speech, he said Hungary would become a country “where no one is stigmatized for loving someone differently than the majority.”
FILE - Participants in the Pride march cross the Elisabeth Bridge in Budapest, Hungary, Saturday, June 28, 2025. (AP Photo/Rudolf Karancsi, File)
MENLO PARK, Calif.--(BUSINESS WIRE)--Apr 21, 2026--
MedaSystems, the leading SaaS platform for Expanded Access (EA), Post-Trial Access (PTA), and Investigator-Initiated Studies (IIS), today announced a significant new platform release, introducing powerful new features and performance enhancements designed to elevate usability, increase flexibility, and strengthen collaboration across the platform. This release reflects our continued commitment to innovation—giving our clients greater control, efficiency, and confidence in configuring and using MedaSystems every day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421632425/en/
“At MedaSystems, we value the feedback provided to us by our users and are constantly looking for ways to help them achieve more, whether by adding new tools to the platform or by helping to reduce the time it takes to complete tasks within the application,” said Jeffrey Thibeault, Co-Founder and CTO. “We're excited to release some of these frequently requested updates.”
A Faster, Smoother, More Reliable Platform
At the core of this release are major performance improvements that make the MedaSystems experience faster and more responsive than ever. Users will notice significantly improved application speed, faster load times, and smoother navigation across key workflows. Enhanced backend optimizations further improve system stability and scalability, ensuring consistent performance—even when working with large datasets or in high-traffic environments. These improvements reflect MedaSystems’ ability to support complex, high-volume programs involving thousands of patients across multiple regions. The platform is designed to maintain consistent performance under real-world operational pressure.
“Performance and reliability are foundational for our customers, especially when supporting global programs at scale,” said Matt Rosen, Co-Founder and EVP. “These enhancements ensure the platform remains fast, stable, and dependable, even in the most demanding environments.”
Consistent with MedaSystems’ commitment to quality and compliance, this release was delivered through the company’s established software lifecycle, validation, and change control processes. Recognizing that compliance is a shared responsibility, MedaSystems provides documentation and validation support to help customers manage change in GxP-relevant environments, including programs aligned with FDA 21 CFR Part 11 and EU Annex 11 expectations, as well as programs collecting real-world data. These enhancements can therefore be adopted with greater confidence in system integrity, traceability, and operational control.
Intuitive Form Builder
Our newly launched Form Builder introduces a modern, highly intuitive interface that dramatically simplifies form creation and editing. With enhanced flexibility and precision, customers now have greater control over every aspect of form design—enabling faster configuration, easier updates, and improved consistency. This advancement supports our long-term vision of empowering clients to fully manage their system configuration without sacrificing ease of use. Combined with MedaSystems’ flexible workflows and communication tools, customers can quickly deploy new forms and questionnaires at any stage of a program. This enables faster adaptation to evolving clinical and regulatory requirements.
Mobile Support for Work Anywhere
To support today’s mobile workforce, MedaSystems now offers optimized mobile access for the most commonly used HCP features. The platform delivers a seamless, responsive experience across all standard screen sizes—from smartphones to tablets—ensuring reliable access, improved efficiency, and consistent performance wherever users need to engage. By extending key functionality to mobile devices, MedaSystems reduces friction in urgent workflows and supports faster response times in high-priority situations. This is particularly important in emergency or compassionate use scenarios.
Expanded Real-Time Chat Functionality
MedaSystems has expanded its real-time chat capabilities to include external communication, building on its existing internal messaging tools. Pharmaceutical companies can now communicate directly with HCPs in real time within the platform—eliminating the need for follow-up emails and enabling faster, more efficient interactions. By centralizing communication, teams can streamline engagement, reduce delays, and improve overall responsiveness. This enhancement reduces reliance on fragmented email threads and ensures that all communication is centralized, auditable, and directly tied to each request. It enables faster decision-making and better coordination across stakeholders.
A More Polished User Experience
In addition to major feature updates, this release includes thoughtful refinements that enhance overall usability and visual consistency. Users will benefit from clearer system messaging, cleaner interface design, and improved consistency across components and workflows—creating a more intuitive and cohesive experience. The refinements reflect ongoing attention to user feedback and a focus on reducing friction across workflows. Together, they contribute to a more seamless and predictable user experience.
About MedaSystems
MedaSystems is the leading developer of secure, GxP‑compliant software for managing requests for experimental therapies—including Expanded Access, Post-Trial Access, and Investigator‑Initiated Studies. By connecting physicians and pharmaceutical companies in a centralized, audit‑ready environment, MedaSystems reduces administrative burden, improves data quality, and helps patients worldwide gain timely access to investigational treatments.
MedaSystems Introduces Next-Generation Enhancements to Transform User Experience
